>While Dr. Cox couldn't yet provide sales/revenue estimates for Atryn in the recent conf call, I was wondering if you guys have any ballpark guestimates?<
$25M during the first twelve months after the establishment of reimbursement in the major EU countries is a reasonable projection.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.